Ticker IRLAListed on Nasdaq

IRulya Therapeutics Inc.

Biological Products, (No Diagnostic Substances)CIK 0001662774New Haven, ConnecticutFilings at SEC EDGAR

At a glance

Most recent filing on November 12, 2026 — a grant by Bonuccelli Catherine M. on Nov 9, 2026.

Since November 12, 2026: 0 open-market purchases and 0 open-market sales.

We hold 5 Form 4 lines, going back to November 12, 2026.

All 5 shown

CEO pay

What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.

Dr. Thye, fiscal year ended Dec 31, 2025: total $2,411,125, actually paid $3,944,367. First reported Apr 27, 2026.

Earlier fiscal years are part of the subscription.